{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:38:25Z","timestamp":1792485505504,"version":"4.5.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"am","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+\/HER2\u2212 OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET\/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>All consecutive patients with HR+\/HER2\u2212 OMBC treated at our institution between 2012 and 2020 were included. OMBC was defined as\u2009\u2264\u20095 metastases. Prognostic factors including biological subtype, anatomical distribution, imaging modality, and LAT were evaluated for overall and progression-free survival (OS, PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 145 patients (median follow-up 82.8 months), median OS and PFS were, respectively, 81.1 and 26.5 months. Luminal-A-like subtypes, absence of liver metastases, and use of MIMs independently predicted better survival. LAT improved PFS (hazard ratio [HR]=0.52; 95%CI[0.29\u20130.91], p=0.0233) and showed a trend toward longer OS. In patients staged with MIMs, LAT significantly improved both OS (HR\u2009=\u20090.29; 95%CI[0.12\u20130.73], p=0.008) and PFS (HR\u2009=\u20090.40; 95%CI[0.21\u20130.77], p=0.0064). After first-line systemic therapy, only 18% developed polymetastatic progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HR+\/HER2\u2212 OMBC, three actionable considerations emerge: staging must incorporate modern imaging to accurately define metastatic burden; LAT may be considered in selected patients with low-grade disease, absence of liver metastases, and long disease-free interval; in oligoprogression after first-line therapy, LAT should be re-evaluated within a multidisciplinary setting. These data offer pragmatic benchmarks to individualize treatment while awaiting definitive randomized evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag413","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:39:38Z","timestamp":1792481978000},"source":"Crossref","is-referenced-by-count":0,"title":["Hormone Receptor\u2013Positive HER2-Negative Oligometastatic Breast Cancer: prognostic stratification and pattern of progression"],"prefix":"10.1093","author":[{"given":"Jean-Louis","family":"Lacaze","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Medical Oncology, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Cabarrou","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Biostatistics & Health Data Science Unit, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Cassou-Mounat","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Radiology, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Chira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Radiotherapy, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Dalmasso","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Radiotherapy, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Maio","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Medical Oncology, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jouve","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Surgery, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Korenbaum","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Medical Oncology, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Massabeau","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Radiotherapy, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Nicolai","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Medical Oncology, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Poumeaud","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Medical Oncology, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Selmes","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Surgery, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mony","family":"Ung","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud , IUCT-Oncopole, Department of Medical Oncology, Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,19]]},"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag413\/72125027\/oyag413.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag413\/72125027\/oyag413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:39:38Z","timestamp":1792481978000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article\/doi\/10.1093\/oncolo\/oyag413\/8943957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag413","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"article-number":"oyag413"}}